ストックスクリーナーアプリを入手
18.11
3.54%
-0.665
前日終値:
$18.77
開ける：
$18.765
24時間の取引高:
2.10M
Relative Volume:
0.96
時価総額：
$1.28B
収益：
-
当期純損益:
$-145.21M
株価収益率:
-7.8717
EPS:
-2.3
ネットキャッシュフロー:
$-140.12M
1週間 パフォーマンス:
+14.81%
1か月 パフォーマンス:
+14.16%
6か月 パフォーマンス:
-67.61%
1年 パフォーマンス:
-57.23%
1日の値動き範囲:
$17.78
$19.49
1週間の範囲:
$15.78
$19.49
52週間の値動き範囲:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.09 | 1.33B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.69 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-15 | ダウングレード | Goldman | Neutral → Sell |
| 2026-01-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-11-03 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | ダウングレード | Goldman | Buy → Neutral |
| 2025-09-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-09-30 | ダウングレード | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2025-09-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-28 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy, safety, and financial runway - TradingView
MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data ReleaseHas The Bull Case Changed? - simplywall.st
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy and safety data - TradingView
MoonLake's sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx - European Biotechnology Magazine
Why Is MoonLake Immunotherapeutics Stock Trading Higher TodayMoonLake (NASDAQ:MLTX) - Benzinga
MoonLake stock surges on positive axSpA trial data By Investing.com - Investing.com India
MoonLake stock surges on positive axSpA trial data - Investing.com
MoonLake stock surges 63% after InvestingPro Fair Value call By Investing.com - Investing.com Canada
US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris - Bloomberg.com
MoonLake Highlights Positive S-OLARIS Data and Investor Day - TipRanks
MoonLake arthritis win kicks off pivotal year for IL-17 nanobody - Fierce Biotech
MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study - marketscreener.com
Swiss biotech MoonLake unveils good trial results and strong cash position - Business Weekly
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown - Stocktwits
MoonLake announces results from Phase 2 trial of Sonelokimab - TipRanks
MoonLake reports positive phase 2 axial spondyloarthritis data By Investing.com - Investing.com Australia
MoonLake reports positive phase 2 axial spondyloarthritis data - Investing.com
MoonLake Immunotherapeutics Reports Promising Phase 2 Results for Sonelokimab in Axial Spondyloarthritis and Financial Updates - Quiver Quantitative
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results - The Manila Times
MoonLake Announces Positive Topline Results from its Phase - GlobeNewswire
Biotechnology company MoonLake Immunotherapeutics announced that its innovative drug Sonelokimab achieved positive topline results in a Phase II clinical trial for axial spondyloarthritis. - Bitget
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX - MarketBeat
What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 Levels & Growth Focused Stock Reports - mfd.ru
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits
MoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.5%Still a Buy? - MarketBeat
MoonLake Immunotherapeutics (MLTX) Stock Analysis: A 25% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Price-Driven Insight from (MLTX) for Rule-Based Strategy - Stock Traders Daily
Will MoonLake Immunotherapeutics announce a stock splitWeekly Trade Recap & Capital Protection Trading Alerts - mfd.ru
Volume Recap: What is the cash position of MoonLake ImmunotherapeuticsWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
Is MoonLake Immunotherapeutics stock heavily shorted2025 Momentum Check & Weekly High Return Opportunities - mfd.ru
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
0.88%
0.77%
大文字化:
|
ボリューム (24 時間):